

VIF World 2025

Event Brochure

Mar.20-22, Shanghai

VIF

Presented by



Vaccine Innovation Forum 2025

(6th edition)

Vaccines of Future: Bridging Science and Society

Mar. 20-22 Shanghai

Background:

VIF World 2025, the Vaccine Innovation Forum, stands as a premier international event dedicated to the advancement of vaccine science and global health. Building on the tremendous success of previous forums, including the groundbreaking VIF World 2024 in Shanghai, this year's conference aims to further cement its reputation as a crucial meeting place for experts, researchers, policymakers, and industry leaders.

Scientific Advisory Board:



Bin Wang
CSO
Advaccine



David Weiner
EVP
The Wistar Institute



George Siber
President
Siber Biotechnologies



Heinrich Hass
Former VP,
BioNTech



Dexiang Chen
Chairman&GM
Maxvax



Chunlin Xin
VP
Cansino Biologics



Alain Bouckennooghe
CSO
Hilleman Laboratories



Linqi Zhang
Professor
Tsinghua University



Dianna Boraschi
Distinguished Professor
Shenzhen Institute of Advanced
Technology



Simon Graham
Professor
The Pirbright Institute



Emanuele Montomoli
Full Prof. of Public Health
University of Siena/CSO,
VisMederi



Li Shi
Board Chairman
Immune-Path Bio



Yuan Yuan
China Country Rep.
PATH



Petro Terblanche
CEO
Afrigen Biologics



Shaowei Li
Professor
Xiamen University



Yuanqing Liu
CSO China
Immorna



Anna Du
Senior Program Officer
Bill & Melinda Gates
Foundation



Joon Haeng Rhee
Professor
Chonnam National University
Medical School



Michel De Wilde
Former SVP, R&D, Sanofi
Pasteur; Owner, MDW
Consultant



Kiat Ruxrungtham
Director, Chula VRC
CHULALONGKORN UNIVERSITY



Sean Du
Head, External R&D, APAC
Sanofi Pasteur



Raman Rao,
CEO, Hilleman Laboratories



Meng Li
Head of Board Office, Director of
International Cooperation,
China National Biotec Group



Xiaofeng Liang
VP, Chinese Preventive Medicine
Association
Professor, Jinan University



Ruben Rizzi
SVP of Global Regulatory
Affairs,
BioNTech



Huichen Guo
Professor
Lanzhou Veterinary Research
Institute



Yuelong Shu
Director General
Institute of Pathogen Biology, CAMS &
PUMC, China



George Fu Gao
Former Director, China CDC
Professor, Chinese Academy of
Sciences

VIF World 2024 Statistics

Total attendee: 409


Speakers: 89

Sponsors: 21


Exhibitors: 17

1-on-1 meetings: 203


By Title



By Industry



By Regions



Testimonia

"I enjoyed the part I was able to attend. It was a great platform for exchange of ideas and for gathering of the beautiful minds. BMGF together with Shanghai S&TC is likely to continue to be a sponsor I think"

—Fujie Xu, Deputy Director, BMGF China Office

"This has been an excellent vaccine innovation conference, which provide great opportunities for attendees to communicate and exchange ideals and potential collaborations."

—Ge Liu, Starna Therapeutics (Suzhou)

"It's a very good event. Excellent! And I would like to be a scientific advisor for next year's program."

—Emanuell Montomoli, CSO Vismederi srl ITALY

"Good conference, some excellent talks. Great to learn about great Chinese science."

—Michel De Wilde, President, MDW Consultant; Former SVP, Sanofi Pasteur

"I thought the event was very well organised with a good blend of speakers from academia and industry. Fewer parallel sessions. Having veterinary vaccines more embedded in the event rather than at the end."

—Simon Graham, Professor, The Pirbright Institute

"Excellent meeting! " —James W. Shih, Senior Advisor, Xiamen Inovax

"This is a very productive event. I had many meetings with potential partners and really enjoyed the talks. "

—Ronen Tchelet, CSO, Dyadic

"Excellent meeting! We had a great pre-conf workshop on QS21 and met a lot of customers. Sure, we will come next year! " —Damian Hiley, Desert King

"Excellent conference! It would be even better if simultaneous interpretation or bilingual Chinese-English PPT could be provided." —Shaoxiong Yu, Senior Scientist, CSPC Jushi Biomedicine

"A very valuable conference!" —Zhao Ling, BD Director, Huzhou Shenke Biotechnology

"Great conference! Conducted entirely in English, it demonstrates good internationalization. It would be beneficial to invite more innovative vaccine research and technology development presentations and avoid solely product data and advertising-style reports. More overseas guests should be invited."

—Yongming Chen, Professor, Sun Yat-sen University

"Overall, the organization is commendable, and I have gained a lot of valuable insights."

—Xiaodan Liu, Senior Project Supervisor, SinoPharm CNBG

"Not bad, full of practical content! It is recommended to provide simultaneous interpretation."


—Gelin Xu, Senior Expert, Wuhan Institute of Biological Products

"A conference of high quality, not only featuring scientific discussions on many new vaccines but also facilitating exchanges on the commercialization of new technologies. " —Frank Chang, CTO, Reber Genetics

"Practical contents and full of gains!" —Chen Zhong, CTO, Suzhou HealiRNA Biotechnology

"A comprehensive vaccine summit integrating "Science-R&D-Industry"!

—Ling Zhang, Director, Recbio Biotechnology



Key Sessions & Topics

Novel Vaccine Innovation:

In the relentless pursuit of combating infectious diseases, the landscape of vaccine innovation has evolved dramatically. This session will delve into the latest breakthroughs in vaccine design, highlighting novel approaches that harness cutting-edge technologies such as synthetic biology, structural vaccinology, and computational modeling. Experts will explore how these innovative strategies are revolutionizing the development of vaccines, enhancing their efficacy, safety, and rapid deployment to combat a wide spectrum of infectious diseases.

Infectious diseases

This track provides a unique opportunity to gain insights into the forefront of infectious disease vaccine research and development, from groundbreaking technologies to global health strategies. Attendees will benefit from engaging with thought leaders, sharing experiences, and fostering collaborations to accelerate the development and deployment of vaccines crucial to preventing and controlling infectious diseases.

RNA Technology

The "RNA Technology" track will bring together leading experts, researchers, and industry professionals to explore the forefront of RNA-based vaccine development. RNA technology has emerged as a groundbreaking platform, revolutionizing the field of vaccinology. This track will showcase the latest breakthroughs, challenges, and applications of RNA-based vaccines, shedding light on their potential to address current and future global health challenges.

Bacterial vaccines

This track will serve as a platform for researchers, clinicians, industry leaders, and policymakers to exchange ideas, share insights, and collaborate on addressing the persistent challenges posed by bacterial infections. Attendees will gain a comprehensive understanding of the latest breakthroughs in bacterial vaccine development, strategies for combating antibiotic resistance, and the pivotal role of vaccination in safeguarding public health.

Veterinary Vaccines:

Beyond human health, veterinary vaccines play a crucial role in safeguarding animal populations and preventing zoonotic diseases. This segment will explore advancements in veterinary vaccine research, emphasizing cross-species protection and the interconnectedness between animal and human health. Renowned experts will share insights into innovative veterinary vaccine strategies, highlighting their impact on agriculture, conservation, and public health.

Cancer Vaccines & Immunotherapies:

Unleashing the immune system against cancer has ushered in a new era of medical possibilities. This topic delves into the cutting-edge field of cancer vaccines and immunotherapies, spotlighting breakthroughs in personalized cancer treatment, tumor antigen discovery, and immune checkpoint modulation. Esteemed speakers will showcase the transformative potential of harnessing the immune system to target and eradicate cancer cells.

Bioprocessing & Manufacturing:

The journey from laboratory discovery to vaccine distribution hinges on robust bioprocessing and manufacturing strategies. This session will provide a comprehensive overview of the intricate processes involved in scaling up vaccine production, ensuring product quality, and optimizing manufacturing efficiency. Leading experts will discuss the latest advancements in bioprocessing techniques, platform standardization, and supply chain resilience.



Clinical Trial/Vaccine Safety:

Rigorous clinical trials and stringent safety assessments are the cornerstones of vaccine development. In this segment, experts will delve into the intricacies of designing and executing vaccine clinical trials, emphasizing the importance of diverse participant representation and ethical considerations. Discussions will also revolve around post-marketing surveillance and risk assessment, underscoring the commitment to ensuring vaccine safety and efficacy.

Market Access/Regulatory/International Partnership:

The journey of a vaccine from the laboratory to the global population involves navigating complex regulatory landscapes and fostering international collaboration. This topic will explore strategies for ensuring equitable access to vaccines, regulatory harmonization, and fostering partnerships between governments, industries, and organizations. Esteemed speakers will discuss the pivotal role of diplomacy and collaboration in promoting global vaccine availability and uptake.


Adjuvant, Formulation, and Delivery Technologies:

In the intricate tapestry of vaccine development, the triumvirate of adjuvants, formulations, and delivery technologies holds a pivotal role in sculpting immune responses and ensuring effective vaccine administration. This session will delve into the forefront of adjuvant research, elucidating their diverse mechanisms in boosting immunity and shaping vaccine outcomes. Moreover, experts will unravel the art of crafting vaccine formulations that balance stability, antigen presentation, and immunogenicity, paving the way for enhanced efficacy and global accessibility.

Young Scientist Poster Session:



One-on-One Meeting System:



Speaker Recruitment

We are inviting qualified speakers worldwide for VIF World 2025. If you are interested, pls feel free to contact us through: sam.li@chstone-events.com

Confirmed Speakers:

Rajinder Suri, CEO, DCVMN International, Switzerland

Raches Ella, Chief Development Officer, Bharat Biotech, India

Hun Kim, President of Global Biz, SK bioscience, South Korea

Mahesh Kumar, SVP of R&D, Global Biologics, Zoetis, USA

Simon Graham, Professor, The Pirbright Institute, UK

Jicui Dong, Unit Head, Local Production & Assistance Unit, Innovation and Emerging Technologies Department (IET),MHP, World Health Organization, Switzerland

Emanuel Montomoli, Professor, Full Prof. of Public Health, University of Siena;CSO of VisMederi Italy

George Siber, President, Siber Biotechnologies LLC, USA

Joon Haeng Rhee, Professor, Chonnam National University Medical School, South Korea

Diana Boraschi, Distinguished Professor, Shenzhen Institute of Advanced Technology, China

Melanie Saville, CSO, PATH, USA

Ken Ishii, Director, International Vaccine Design Center, Professor, University of Tokyo, Japan

Nikolai Petrovsky, Founder, Vaxine, Australia

Adrian V. S. Hill, Director, The Jenner Institute, Lakshmi Mittal & Family Professor of Vaccinology, University of Oxford , UK

Ruben Rizzi, Senior Vice President Global Regulatory Affairs, BioNTech, Germany

Simona Rondini, Head of GVGH Bacterial Projects, Senior Project Leader Salmonella Typhi/Paratyphi A , GSK Vaccines for Global Health (GVGH), Italy

Raman Rao, CEO, the Hilleman Laboratories, Singapore

Meng Li, Head of Board Office, Director of International Cooperation, China National Biotec Group, China

Bin Wang, Professor, Fudan University/CSO, Advaccine, China

Linqi Zhang, Professor, Tsinghua University, China

Shaowei Li, Professor, Xiamen University, China

Nigel Temperton, Professor, Director, Viral Pseudotype Unit, University of Kent, UK

Kiat Ruxrungtham, Professor of Medicine, Director of Chula VRC, Chulalongkorn University, Thailand

Xiaofeng Liang, VP, Chinese Preventive Medicine Association; Professor, Jinan University, China

Tongqing Zhou, Chief, Structural Bioinformatics Section National Institutes of Health, USA

Dan Barouch, Professor, Harvard Medical School; Director, Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center, USA

Shibo Jiang, Professor, Fudan University, China

Wei Tan, SVP, Head of China Research and External Collaboration, Clover Biopharmaceutical, China

Huichen Guo, Professor, Lanzhou Veterinary Research Institute, China

Baik-Lin Seong, Director General, Vaccine Innovative Technogy ALliance (VITAL)-Korea, South Korea

Christopher Netherton, Professor, The Pirbright Institute, UK

Nibal Dahaba, Co-Founder & General manager Emerging markets, Genneccs Holding, Egypt

Jiguo (Jeffrey) Zhang, President, Vaccine Division, Fosun Pharma, China

Petro Terblanche, CEO, Afrigen Biologics, South Africa

Zhaohua (Jessie) Chen, Head of Development China, General Manager of China R&D, Pfizer, China

Yuelong Shu, Director, Institute of Pathogen Biology, CAMS & PUMC, China

Robbert van der Most, Former VP, Translational Science Infectious Diseases, BioNTech; CEO, VaxxCellence, Germany

Jingxin Li, Vice Director of the Department, Jiangsu CDC, China

George Fu Gao, Former Director, China CDC; Professor, Chinese Academy of Sciences, China

Linfa Wang, Professor, Duke-NUS Medical School, Singapore

Nicaise Ndemi, Head for Partnerships for African Vaccine Manufacturing (PAVM) & Head Science Office, Africa CDC, Ethiopia

Yunlong Richard Cao, Assistant Professor, Peking University, China

Amine Kamen, Professor, McGill University, Canada

Lianpan Dai, Professor, Institute of Microbiology, Chinese Academy of Sciences, China

Han Wang, Associate Professor, Peking University, China

Patrícia Neves, Project Manager, mRNA center, Bio-Manguinhos/ Fiocruz, Brazil

Adel Sattarova, Head of Project activity department, FSUE SPbSRIVS FMBA of Russia

SeyedReza Banihashemi, Director of R&D, Razi Vaccine & Serum Research Institute, Iran

Norbert Pardi, Associate Professor, University of Pennsylvania, USA

Hani Kim, Executive Director, RIGHT Foundation, South Korea

Jian Dong, CEO, WuXi Vaccines; SVP, WuXi Biologics, China

Qihan Li, Professor, Weirui Bio, China

Sean Du, Head, External R&D APAC, Global R&D, Sanofi Pasteur, China

Heinrich Haas, CTO, NeoVac, UK

Kate Broderick, Chief Innovation Officer, Maravai Life Sciences, USA

Landian Hu, CEO, Anda Biology Medicine Development (Shenzhen), China

Adham Rezk, CEO, Celero, Singapore

Hong Jin, CSO, CyanVac, USA

Nguyen Tuyet Nga, South East Asia Hub Director/Vietnam Country Director, PATH, Vietnam

Peter L. Andersen, Chief Scientific Advisor, Infectious Diseases, Novo Nordisk Foundation, Denmark

Xiangrong Song, Cofounder & CEO, Westgene, China

Jie Li, Head of R&D, The Spirit Jinyu Biological Pharmaceutical, China

Suthira Taychakhoonavudh, CEO, Baiya Phytopharm, Thailand

Dexiang Chen, CEO, Maxvax, China

Deog-Young Choi, CEO, InThera, South Korea

Yelin Xiong, VP, Yither Biotech, China

Francesca Ceddia, Chief Medical Affairs Officer, Moderna, USA

Zihao Wang, CEO, Immorna Bio, China

Francesco Berlanda Scorza, VP, R&D, Global Health R&D Vaccines Head and GVGH Institute Director, GSK, Italy

Bo Ying, Co-founder, Chairman & CEO, Abogen Biosciences, China

Peter Dull, Deputy Director at Bill & Melinda Gates Foundation, USA

Jiangsheng Xu, Co-founder & CSO, General Therapeutics, USA

Emanuele Andreano, Project Leader, Fondazione Toscana Life Sciences, Italy

Hao Chen, AVP, Head of Vaccines & Advanced Biotechnologies Process R&D, Merck, USA

Hao Li, Associate Professor, China Agricultural University, China

Xuexiang Han, Professor, SIBCB, China

Frank Chang, CTO, Reber Genetics, China

Haibo Li, Professor, Army Medical University, China

Keith Chappel, Group Lead, The university of Queensland, Australia

Ying Mazzu, COB & CSO, Nanjing AuroRNA Biotechnology, China

Frank Chang, CTO, Reber Genetics, China

Keith Chappel, Group Leader, The University of Queensland, Australia

Ling Chen, Professor, Guangzhou Laboratory, China

Chunying Chen, Academician, Professor, The National Center for Nanoscience and Technology, CAS, China

David Weiner, Executive VP, Wistar Institute, USA

Jason McLellan, Professor, University of Texas at Austin, USA

Baoming Jiang, Team Lead, US CDC, USA

Dong Yu, VP R&D, Dynavax Technologies, USA

Tonya Villafana, Vice President, Global Franchise Head, mAbs and Head of Scientific Affairs, AstraZeneca, USA

Tim Hirst, CEO, GPN Vaccines, Australia

More leading speakers to be announced.

VIF World 2025 Agenda

Day 1 Mar. 20

Morning Plenary Session

0900 Plenary Panel: Revolutionizing Global Health: The Future of Vaccine Technology and Innovation

The global pandemic has accelerated innovation in vaccine development, pushing forward technologies like mRNA and viral vector platforms. As we move toward the next decade, the question remains: how can we ensure these breakthroughs continue to revolutionize healthcare globally? This panel will explore emerging vaccine platforms, personalized vaccines, and the role of AI in streamlining vaccine research.

0945 Plenary Panel: Global Vaccine Equity: Overcoming Challenges in Distribution and Access

While significant progress has been made in developing vaccines for diseases like COVID-19, achieving equitable distribution remains a challenge. This panel will focus on addressing global disparities in vaccine access, including the role of international cooperation, local manufacturing, and public-private partnerships.

1030 Tea Break

1100 Keynote: Innovative Vaccine Platforms: Accelerating Global Health R&D (TBD)

Francesco Berlanda Scorza, VP, R&D, Global Health R&D Vaccines Head and GVGH Institute Director, GSK, Italy

1125 Keynote: TBC

Dan Barouch, Professor, Harvard Medical School; Director, Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center, USA

1150 Keynote: TBD

1230 Lunch

Day 1 Mar. 20

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2025 Agenda

Afternoon Session

Respiratory diseases/Flu/Covid	Cancer vaccine & immunotherapy	DCVMN Forum	Mucosal immunization
<p>1330 Pan-sarbecoV vaccine: a dream or reality? Linfa Wang, Professor, Duke-NUS Medical School, Singapore</p> <p>1355 Pan-Corona vaccine development (TBC) Shibo Jiang, Professor, Fudan University, China</p> <p>1420 TBC</p> <p>1445 TBC Wei Tan, SVP, Head of China Research and External Collaboration, Clover Biopharmaceutical, China</p> <p>1500 Clinical development for RSV vaccine in China (TBD) Zhaohua (Jessie) Chen, Head of Development China, General Manager of China R&D, Pfizer, China</p> <p>1525 Tea Break</p> <p>1545 TBC Linqi Zhang, Professor, Tsinghua University,</p>	<p>1330 TBD David Weiner, EVP, The Wistar Institute, USA</p> <p>1355 Development of mRNA vaccines: from infectious diseases to oncology Ruben Rizzi, Senior Vice President Global Regulatory Affairs, BioNTech, Germany</p> <p>1420 TBC</p> <p>1445 TBC</p> <p>1510 Precision treatment of pancreatic cancer - personalized tumor treatment vaccine Landian Hu, CEO, Anda Biology Medicine Development (Shenzhen)</p> <p>1525 Tea Break</p> <p>1545 Therapeutic vaccine development for Cancer Bin Wang, Professor, Fudan University/Founder, Advaccine, China</p> <p>1610 TBC</p>	<p>1330 Strengthening Vaccine Manufacturing Capacity in Developing Countries: The Role of DCVMN Rajinder Suri, CEO, DCVMN International, Switzerland</p> <p>1355 Overview of HPV vaccine development and global vaccine introduction status Peter Dull, Deputy Director at Bill & Melinda Gates Foundation, USA</p> <p>Innovative Vaccine Platforms: Leveraging Global Collaboration for Pandemic Preparedness Raches Ella, Chief Development Officer, Bharat Biotech, India</p> <p>Building vaccine capability in Africa (TBC) Nicaise Ndembi, Head for Partnerships for African Vaccine Manufacturing (PAVM) & Head Science Office, Africa CDC, Ethiopia</p> <p>Development of the vaccine production facility and tech transfer in Latin America</p>	

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2025 Agenda

<p>China</p> <p>1610 TBC</p> <p>1635 Addressing next potential pandemic of avian flu (Panel) (TBC) Yuelong Shu, Director, Institute of Pathogen Biology, CAMS & PUMC, China</p> <p>1730 End of session</p>	<p>1625 TBD Xiangrong Song, Cofounder & CEO, Westgene, China</p> <p>1640 Therapeutic HPV vaccine Ying Mazzu, COB&CSO, Nanjing AuroRNA Biotechnology, China</p> <p>1730 End of session</p>	<p>Adel Sattarova, Head of Project Management Department, FSUE SPbSRIVS FMBA of Russia</p> <p>Innovative products for low resource settings Melanie Saville, CSO, PATH, USA</p>	
---	--	---	--

Day 2 Mar. 21

Morning Session

Biomanufacturing & Formulation	Emerging & Re-emerging	Vaccine Design and Preclinical	RNA Technologies
<p>0900 Building Sustainable Local Vaccine Manufacturing: WHO's Support for Low-Resource Settings Jicui Dong, Unit Head, Local Production & Assistance Unit, Innovation and Emerging Technologies Department (IET), MHP, World Health Organization, Switzerland</p> <p>0925 Advanced technology platforms for vaccine manufacturing in response to pandemic situations Amine Kamen, Professor, McGill University, Canada</p>	<p>0900 Malaria Vaccines: from Licensure to Elimination Adrian V. S. Hill, Director, The Jenner Institute, Lakshmi Mittal & Family Professor of Vaccinology, University of Oxford, UK</p> <p>0925 Rational design of Zika vaccine to eliminate dengue enhancement Lianpan Dai, Professor, Institute of Microbiology, Chinese Academy of Sciences, China</p>	<p>0900 Next-Generation Vaccine Platforms: A Blueprint for Global Preparedness Ken Ishii, Director, International Vaccine Design Center, Professor, University of Tokyo, Japan</p> <p>0925 Epitope Mapping and Structural Vaccinology: Advances in Antigen Design Shaowei Li, Professor, Xiamen University, China</p> <p>0950 TBC</p> <p>1015 TBC</p>	<p>0900 Lipid nanoparticles for mRNA vaccine delivery Pardi Norbert, Associate Professor, University of Pennsylvania, USA</p> <p>0925 mRNA Vaccines in Low- and Middle-Income Countries: Bridging the Gap Kiat Ruxrungham, Professor of Medicine, Director of Chula VRC, Chulalongkorn University, Thailand</p> <p>0950 TBC</p> <p>1020 RNA platform implementation in</p>

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2025 Agenda

0950 Next-Generation Vaccine Manufacturing: Scaling Innovation for Global Health (TBD)
Jian Dong, CEO, WuXi Vaccines; SVP, WuXi Biologics, China

1005 TBC

1035 Tea Break

1100 Next-Generation Vaccine Platforms: Innovations in Process Development (TBD)
Hao Chen, AVP, Head of Vaccines & Advanced Biotechnologies Process R&D, Merck, USA

0940 Innovative immunogen design for mpox virus vaccine development
Han Wang, Associate Professor, Peking University, China

0955 TBC

1020 “DengiALL” Panacea Biotec’s tetravalent Dengue vaccine
Syed Khalid Ali, Chief Scientific Officer, Panacea Biotec, India (Invited)

1035 Tea break

1100 Challenges and perspectives on development of Dengue vaccine
Fernanda Boulos, Chief Scientific Officer, Instituto Butantan, Brazil (Invited)

1115 6-Valent Virus-Like Particle-Based Vaccine development against Norovirus
Dongming Zhou, Head of R&D, Chengdu Kanghua Biological Products Co., China (Invited)

1130 TBC

1200 Assembly of Virus-like Particles Harnessed with RNA-based Chaperone
Baik-Lin Seong, Director General, Vaccine Innovative Technology Alliance (VITAL)-Korea, South

Tongqing Zhou, Chief, Structural Bioinformatics Section National Institutes of Health, USA

1035 Tea Break

1100 AI-Guided and Structure-Based Vaccine Design

George Fu Gao, Former Director, China CDC; Professor, Chinese Academy of Sciences, China

1125TBD

Qihan Li, Professor, Weirui Bio, China

1150 TBC

1215 TBC

1230 Lunch

Brasil: Seeding the innovation ecosystem in Latin America

Patrícia Neves, Project Manager, mRNA center, Bio-Manguinhos/ Fiocruz, Brazil

1035 Tea break

1100mRNA vaccines and global health: addressing global unmet needs in infectious diseases

Ruben Rizzi, Senior Vice President Global Regulatory Affairs, BioNTech, Germany

1125 TBC

1155 TBD

Heinrich Hass, CTO, NeoVac, UK

1210 Enhancing the potency of RNA vaccines through next-generation modifications
Kate Broaderick, Chief Innovation Officer, Maravai Life Sciences, USA

1230 Lunch

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2025 Agenda

	<p>1215 A quadrivalent mRNA vaccine candidate elicited potent immune responses against monkeypox virus and protection in a rodent model Yelin Xiong, VP, Yither Biotech, China</p> <p>1230 Lunch</p>		
Biomanufacturing & Formulation	Clinical trial	Vaccine Tech Innovation	RNA Technologies
<p>Enhancing Mucosal Immunity with RAR Agonists as Potent Vaccine Adjuvants Hibo Li, Professor, Army Medical University</p> <p>Adjuvanted recombinant vaccine development for infectious diseases Dexiang Chen, CEO, Maxvax, China</p> <p>Harnessing the power of TLR agonists as vaccine adjuvants Nikolai Petrovsky, Founder, Vaxine, Australia</p> <p>TBD Joon Haeng Rhee, Professor, Chonnam</p>	<p>1330 TBD Jingxin Li, Vice Director of the Department, Jiangsu CDC, China</p> <p>1355 TBC</p> <p>1410 Reduced dose HPV vaccine development Ting Wu, Professor, Xiamen University (TBC)</p> <p>1435 Clinical trial for Maternal vaccine development TBC</p>	<p>1330 Innovative Delivery Methods for Next-Generation Vaccines: Nasal, Inhalable, and Beyond SeyedReza Banihashemi, Director of R&D, Razi Vaccine & Serum Research Institute, Iran</p> <p>1345 The Molecular Clamp Platform: A broadly applicable solution to the manufacture of multivalent subunit vaccines for respiratory viruses Keith Chappel, Group Lead, The university of Queensland, Australia</p> <p>1400 Innovating Plant-Based Vaccines: A</p>	<p>1330 Revolutionizing Therapeutics with Next-Generation RNA Platforms: From Vaccines to Gene Therapy(TBD) Zihao Wang, CEO, Immorna Bio, China</p> <p>1345 Expanding the Frontier: mRNA Vaccines for Cancer and Autoimmune Diseases(TBD) Bo Ying, Co-founder, Chairman&CEO, Abogen Biosciences, China</p> <p>1400 Non-reactogenic LNPs addressing mRNA vaccination hesitancy Jiangsheng Xu, Co-founder&CSO, General Therapeutics, USA</p>

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2025 Agenda

<p>National University Medical School, South Korea</p> <p>TBD</p> <p>Chunying Chen, Academician, Professor, The National Center for Nanoscience and Technology, CAS, China</p>	<p>1500 Clinical strategy for the immunocompromised</p> <p>TBC</p> <p>1525 Tea Break</p> <p>1555 Vaccine clinical development strategy in emerging market(s) and Commercial potentials</p> <p>Adham Rezk, CEO, Celero Global, Singapore</p>	<p>New Frontier in Global Health</p> <p>Suthira Taychakhoonavudh, CEO, Baiya Phytopharm, Thailand</p> <p>1415 TBD</p> <p>Deog-Young Choi, CEO, InThera, South Korea</p>	<p>1415 Next-Generation Lipid Nanoparticle Systems for Targeted RNA Delivery</p> <p>Xuexiang Han, Professor, SIBCB, China</p>
--	---	---	---

Day 3 Mar. 22

Morning Session

AMR	One Health	Preclinical Immunobiology	Partnership & Market access
<p>0900 Revolutionizing Vaccine Development: Lessons from a Lifetime in Immunology</p> <p>George Siber, President, Siber Biotechnologies LLC, USA</p> <p>0925 Tackling Maternal and Neonatal Infections: The Role of Group B Streptococcus Vaccines"</p> <p>Per Fischer, CEO, MinervaX, Denmark (Invited)</p> <p>0940 Immunotherapy and Vaccine Synergy: A New Frontier in Infectious Disease</p>	<p>0900 Innovations in Veterinary Biologics: Navigating the Future of Animal Health</p> <p>Mahesh Kumar, SVP of R&D, Global Biologics, Zoetis, USA</p> <p>0925 Cross-Species Transmission of Animal Viruses: Prevention and Control Strategies</p> <p>Simon Graham, Professor, The Pirbright Institute, UK</p> <p>0950 Immunological Insights into Animal Disease Control: A Path Toward Enhanced Vaccine Efficacy</p>	<p>0900 Innate Immunity and Vaccine Adjuvant Innovation: Leveraging the Body's First Line of Defense</p> <p>Diana Boraschi, Distinguished Professor, Shenzhen Institute of Advanced Technology, China</p> <p>0925 Vaccine adjuvants, mRNA mode of action, innate/trained immunity for vaccines</p> <p>Robbert van der Most, Former VP, BioNTech; CEO, VaxxCellence, Germany</p> <p>0950 Bioassay for vaccine efficacy</p>	<p>Hun Kim, President of Global Biz, SK bioscience, South Korea</p> <p>Raman Rao, CEO, the Hilleman Laboratories, Singapore</p> <p>Meng Li, Head of Board Office, Director of International Cooperation, China National Biotec Group, China</p> <p>Xiaofeng Liang, VP, Chinese Preventive Medicine Association; Professor, Jinan University, China</p>

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2025 Agenda

<p>Treatment Bruno Santos, CEO, Immunetep, Portugal (Invited)</p> <p>0955 Pioneering New Horizons in Bacterial Vaccines: From Concept to Clinical Application Michael Kowarik, Co-Founder & Chief Scientific Officer, LimmaTech, Switzerland (Invited)</p> <p>1010 TBC</p> <p>1035 Tea break</p> <p>1100 Isolation of protective monoclonal antibodies and development of novel fusion protein vaccines against tuberculosis Hao Li, Associate Professor, China Agricultural University, China</p> <p>1115 Harnessing mRNA Technology to Combat Antimicrobial Resistance: Pioneering Vaccines for Drug-Resistant Bacteria Caiyi Fei, VP, TheraRNA, China</p> <p>1130 TBC</p> <p>1200 TBC</p> <p>1230 Lunch</p>	<p>Huichen Guo, Professor, Lanzhou Veterinary Research Institute, China</p> <p>1015 TBC</p> <p>1035 Tea Break</p> <p>1100 Advancing ASFV Vaccine Development: Overcoming the Challenges in Combatting African Swine Fever Christopher Netherton, Professor, The Pirbright Institute, UK</p> <p>1125 Revolutionizing Animal Vaccine Development: The Role of mRNA and Exosome Platforms Jie Li, Head of R&D, The Spirit Jinyu Biological Pharmaceutical, China</p> <p>1140 Progress on the ASF DNA vaccine development in Philippines Frank Chang, CSO, Reber Genetics, China</p> <p>1155 TBC</p> <p>1230 Lunch</p>	<p>Emanuel Montomoli, Professor, Full Prof. of Public Health, University of Siena;CSO of VisMederi Italy</p> <p>1005TBC Yunlong Richard Cao, Assistant Professor, Peking University, China</p> <p>1030 Tea Break</p> <p>1100 TBC</p> <p>1130 Immunogenicity testing of pan-variant influenza and coronavirus vaccines using pseudotype platform technologies Nigel Temperton, Professor, Director, Viral Pseudotype Unit, University of Kent, UK</p> <p>1145 Antigenic sin drives B cell evolution: lessons learned from the COVID-19 pandemic Emanuele Andreano, Project Leader, Fondazione Toscana Life Sciences, Italy</p> <p>1230 Lunch</p>	<p>Nibal Dahaba, Co-Founder & General manager Emerging markets, Gennecs Holding, Egypt</p> <p>Jiguo (Jeffrey) Zhang, President, Vaccine Division, Fosun Pharma, China</p> <p>Hani Kim, Executive Director, RIGHT Foundation, South Korea</p> <p>Sean Du, Head, External R&D APAC, Global R&D, Sanofi Pasteur, China</p> <p>Peter L. Andersen, Chief Scientific Advisor, Infectious Diseases, Novo Nordisk Foundation, Denmark</p>
---	--	--	--

Contact us through sam.li@chstone-events.com or 86-13482341046